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Background.Acutecoronarysyndromes(ACSs)areclinicallycardiovasculareventsassociatedwithdyslipidemiaincommon.Single
nucleotide polymorphisms (SNPs) and haplotypes in the APOA1/C3/A5 gene cluster are associated with diabetes and familial
combined hyperlipidaemia (FCH). Little is known about whether the polymorphisms in these genes aﬀect lipid homeostasis in
patients with ACSs. The present paper aimed to examine these associations with 4 SNPs in the APOA1 −75G > A, the APOC3
−455T > C, and APOA5 −1131T > C, c.553G > T variant to ACSs in Chinese Han. Methods. Chinese Han of 229 patients with
ACSs and 254 unrelated controls were analyzed. Four SNPs in APOA1/C3/A5 cluster were genotyped and lipid was determined.
Results.Our data show that minor allelic frequencies of APOC3 −455T > C, APOA5 −1131T > C, and c.553G > T polymorphisms
in patients with ACSs were signiﬁcantly higher than control group (P<0.05). Furthermore, the 3 polymorphic sites were strongly
of linkage disequilibrium, and minor alleles of 3 SNP sites had higher TG level than wild alleles (P<0.05), APOC3 −455C
and APOA5 c.553T allele carriers also had lower level of HDL-C. Conclusions. The minor alleles of APOC3 −455T > C, APOA5
−1131T > C, and c.553G > T polymorphisms are closely associated with ACSs.
1.Introduction
Acute coronary syndromes (ACSs), including unstable
angina(UA)andacutemyocardialinfarction(AMI),areclin-
ically cardiovascular events resulted from the rupture of
atherosclerotic plaque, followed by inﬂammation associated
with acute-phase response. Atherosclerosis, the major event
leading to ACSs, is characterized by the events following
accumulation of lipids and ﬁbrous elements in coronary
arteries, several risk factors such as genetic and environmen-
tal have been identiﬁed; most importantly levels of HDL,
triglycerides,lipoprotein(a),diabetesmellitus,smoking,and
hypertension [1, 2]. Meanwhile, dyslipidemia is common
and associated with increased mortality rates in hospitalized
patients with ACS [3]. Dyslipidemia often occurs in ACSs
patients, however, the incidence of underlying mechanisms
in this disease remain poorly understood. The Apolipopro-
tein A1-C3-A4-A5 gene cluster on chromosome 11q23
(Apo11q) is among the most well-characterized regions
of the human genome with reference to their dynamic
association with plasma lipids and lipoproteins [4]. The
associated haplotypes constitute a highly informative genetic
marker [5].
Extensive interactions both within and between the
genetic variants within this cluster contribute to the quanti-
tative variation in the blood lipid phenotypes [6]. The SNPs
in the Apo11q region, particularly the −455T > C of the
APOC3 gene [7], as well as −1131C > Tp r o m o t e rS N Pa n d2 Journal of Biomedicine and Biotechnology
S19W SNP in exon 2 of the APOA5 gene [8, 9], have been
shown to independently and in tandem, regulate plasma TG
levels [10]. The two promoter SNPs, −75G > A and +83C >
T in the APOA1 gene, have shown strong association with
HDL-C and ApoA1 levels [11].
The aim of this study was to analyze the relationship of
SNPs in the APOA1/C3/A4/A5 cluster with ACSs in Chinese
Han.
2.MaterialsandMethods
2.1. Study Population. The patient group consisted of 229
unrelated patients ranging in age from 40 to 75 years old
(mean, 59 years old); all had symptoms of ischemia that
were veriﬁed by electrocardiography [ST segment depression
(≥0.1mm), T-wave inversion (≥0.1mm)], or increased
levels of biochemical markers (creatine kinase myoglobin
binding isoenzyme [CK-MB], >6.6μg/L or troponin I [TnI],
>0.3μg/L [0.3ng/mL]). The diagnosis of ACS was estab-
lished on the basis of current deﬁnitions [12].
Control group consisted of 254 unrelated healthy people
all in mean age at 59 years old. The inclusion criteria
for the control group were without a clinical history of
CVD, cardiovascular risk factorshistory, or diagnosis of
atherosclerosis, vascular disease, chronic heart failure, and
arrhythmias, diabetes mellitus, or cancer, and those with
a normal electrocardiograph and normal blood chemistry
values were included.
After an overnight fast for a minimum of 12h, blood
was drawn into EDTA-containing tubes for analysis of lipid
proﬁles. Plasma was prepared by immediate centrifugation
(1,800g, 15min, 4◦C), and samples were stored at −80◦C
until further analyses. Serum total cholesterol, low-density
lipoprotein (LDL) cholesterol, HDL cholesterol, and triglyc-
eride (TG) concentrations weremeasured enzymaticallyon a
Hitachi7450Analyzer(Hitachi,Japan)usingRochereagents.
2.2. Genetic Analysis. DNA was isolated from peripheral
blood leukocytes by a standard salting out method. Details
of PCR primers, annealing conditions, and restriction
enzyme digestion were according to others [13–15]. In short,
the genomic regions encompassing the polymorphic sites
were PCR ampliﬁed using site-speciﬁc primers, restriction
digested with appropriate restriction enzymes (Msp I restric-
tion enzyme for APOA1 −75G > A and APOA5 c.553G > T,
BseG I for APOC3 −455T > C, Mse I for APOA5 −1131T >
C), and the digests were resolved on 2% agarose gel for the
APOA1 and the APOA5 SNPs, while the APOC3 genotypes
were resolved by 6% polyacrylamide gel electrophoresis
(PAGE).
2.3. Statistical Analysis. The statistical analyses were carried
out with SPSS 14.0 software. All data are expressed as
mean ± standard deviation (SD). Frequencies of the alleles
were estimated by gene counting. Agreement of genotype
frequencies with Hardy-Weinberg equilibrium expectations
was tested using χ2 test. The clinical characteristics of study
subjects were compared by unpaired Student’s t-test. The
Table 1: General clinical information and blood fat concentration






Gender (male/female) 128/101 137/117 NS
Age (mean year) 59.1 ± 9.4 59.3 ± 9.6 NS
BMI (kg/m2) 23.24 ± 3.26 22.75 ± 2.97 <0.01
SBP (mmHg) 126.10 ± 12.43 121.93 ± 3.10 <0.01
DBP (mmHg) 74.4 ± 4.6 74.8 ± 4.8 NS
Total cholesterol
(TC, mmol/L) 5.04 ± 1.33 4.77 ± 1.07 <0.01
Triglyceride
(TG, mmol/L) 2.02 ± 0.52 1.38 ± 0.39 <0.01
HDL-C (mmol/L) 1.03 ± 0.34 1.28 ± 0.31 <0.01
LDL-C (mmol/L) 3.87 ± 0.91 2.44 ± 0.68 <0.01
Blood glucose (mmol/L) 5.04 ± 1.33 4.77 ± 1.07 <0.01
Systolic blood pressure and diastolic blood pressure. ACS: coronary artery
disease; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-
density lipoprotein.
lipid levels diﬀerence among every genotype were tested
with ANCOVA. The χ2 test was used to compare the
qualitative data. Logistic regression analysis models were
used to evaluate the haplotypes as possible risk factors. To
determine the extent of LD in our sample, standardized LD
coeﬃcients D  was calculated for all pairs of polymorphisms.
3. Results
3.1. Characteristics of Controls and Patients. General charac-
teristics of 229 ACS patients and 254 healthy controls are
shown in Table 1. ACS patients showed higher systolic blood
pressure, TG, total and LDL-cholesterol, and glucose but
lower HDL-cholesterol levels than controls.
3.2. Allele Frequency and Linkage Disequilibrium. Genotype
distributions for these polymorphisms were in Hardy-
Weinberg equilibrium. As shown in Table 2, the minor allelic
frequencies of −1131T > C and c. 553G > Tp o l y m o r p h i s m s
of APOA5 in patients with ACS (41.3% and 9.8%) were
signiﬁcantly higher than those of the control subjects (31.1%
and 4.9%, resp.). Frequency of C allele of APOC3 −455T >
C in patients with ACS was also signiﬁcantly higher than that
of normal subjects (26.9% and 17.3%, resp.). However, this
diﬀerence was not observed in that of APOA1 −75G > A
(P>0.05) (Table 2).
To determine the extent of LD in our study sample,
standardized LD coeﬃcients D  was calculated for all pairs
of polymorphisms. Table 3 shows the LD matrix generated
using D . As shown in Table 3, except for APOA1 −75G > A,
the other 3 polymorphic sites were in strong linkage disequi-
librium (D  > 0.8).
3.3. Lipid Level and Association Analysis. We found that
APOC3 −455T > C, APOA5 c.553G > T, and −1131T > CJournal of Biomedicine and Biotechnology 3
Table 2:ComparisonofgenotypefrequenciesandHardy-Weinbergequilibriumtestresultsofthefourpolymorphismsintheapolipoprotein
A1/C3/A5 gene cluster between control and ACS group.
ACS Controls
P
(n = 229) (n = 254)
APOA1 −75G > A
GG 41% (94) 42.5% (108)
GA 41.5% (95) 48.8% (124) 0.012
AA 17.5% (40) 8.7% (22)
G 61.8% (283) 66.9% (340)
A 39.2% (175) 33.1% (168) 0.096
APOC3 −455T > C
TT 20% (46) 26.4% (67)
TC 50% (115) 53.9% (137) 0.026
CC 30% (68) 19.7% (50)
T 73.1% (207) 82.7% (271)
C 26.9% (251) 17.3% (237) 0.012
APOA5 −1131T > C
TT 38.9% (89) 52% (132)
TC 39.7% (91) 33.9% (86) 0.01
CC 21.4% (49) 14.1% (36)
T 58.7% (269) 68.9% (350)
C 41.3% (189) 31.1% (158) 0.001
APOA5 c.553G > T
GG 81.2% (186) 90.9% (231)
GT 17.9% (41) 8.3% (21) 0.007
TT 0.9% (2) 0.8% (2)
G 90.2% (413) 95.1% (483)
T 9.8% (45) 4.9% (25) 0.003
Table 3: Standardized linkage disequilibrium coeﬃcient (D )
among four APOA1/C3/A5.
APOC3 APOA5 APOA5
−455T > C −1131T > C c.553G > T
APOA1 −75G > A 0.19 0.20 0.05
APOC3 −455T > C 0.83 0.86
APOA5 −1131T > C0 . 9 2
SNPswereallsigniﬁcantlyassociatedwithlipidlevels.Specif-
ically, the minor allele’s carrier of the three SNPs showed
a signiﬁcant higher triglyceride, and APOC3 −455C and
APOA5 c.553T allele carriers also showed a signiﬁcant lower
HDL cholesterol level than subjects with wild genotypes
(Table 4). No signiﬁcant diﬀerences of triglycerides and HDL
cholesterollevelsgenotypeswerefoundinAPOA1−75G>A.
Multiple logistic regression for best selection model in
above genotypes after adjusting age, gender, and body mass
index is shown in Table 5; we can see that except for APOA1
−75G > A, the minor allele of each of other three polymor-
phisms (APOC3 −455T > C, and the APOA5, −1131T > C
and c.553G > T) were associated with ACS.
4. Conclusion
In this study, the frequency of the APOA5 c.553T allele in
ACS patient group was signiﬁcantly higher than that of
the controls. Compared with the participants with major
alleles (APOA5 −1131TT and c.553GG), those homozygous
for both SNPs (APOA5 −1131CC and c.553TT) had higher
triglyceride concentrations (Table 4). Subjects homozygous
for c.553TT also had higher HDL-C than those with
c.553GG. All these data suggested the importance of APOA5
in the regulation of plasma triglyceride concentrations.
Furthermore, pair wise linkage disequilibrium compari-
son performed in this study betweenAPOC3 and APOA5
demonstrated that they are linked (D  < 0.8), suggesting
cooperation mechanisms for the associations with plasma
lipoproteins and related traits.
5. Discussion
ACSs are a multifactor disease in which a multitude of
lifestyle and genetic factors contribute to the development
and outcome of the disease [16]. Many papers show that
apolipoprotein A1/C3/A4/A5 gene cluster is associated with
premature coronary artery disease [17] and serum lipid
levels [18–25]. Recent ﬁndings indicate that APOA5 could
also inﬂuence cholesterol homeostasis and probably play a
role in hypertriglyceridemia associated with diabetes and
inﬂammation [20].
The frequency of APOC3 −455C allele in ACSs patients
was signiﬁcantly higher than that of normal subjects. This
genetic variation was associated with variation in plasma
concentrations of TG and HDL cholesterol in a manner
consistent with many other reports from diverse populations
[26,27].Speciﬁcally,wefoundthattheCallelewasassociated4 Journal of Biomedicine and Biotechnology
Table 4: Comparison of HDL-C and TG level of the four polymorphisms in the apolipoprotein A1/C3/A5 gene cluster of the study
participants.
TG(483) HDL-C(483)
Mean ± SD P Mean ± SD P




GA + AA 1.58 ± 0.34 1.17 ± 0.24




TC + CC 2.06 ± 0.45 1.04 ± 0.30




TC + CC 2.09 ± 0.44 1.10 ± 0.38




GT + TT 2.02 ± 0.48 0.97 ± 0.31
Table 5: Odds ratios of ACS and 95% conﬁdence intervals (CI) in relation to the presence of diﬀerent alleles of apolipoprotein gene after
a d j u s t i n gf o ra g e ,g e n d e r ,a n dB M Iv a l u e s .
Variable Odds ratio (95% CI) P
APOA1 −75G > A (AA and GA)/GG 0.913 (0.6358–1.313) NS
APOC3 −455T > C (GG and GC)/CC 2.043 (1.413–3.956) 0.000
APOA5 −1131T > C (CC and CT)/TT 3. 702 (2.185–5.445) 0.001
APOA5 c.553G > T (TT and TG)/GG 2.344 (1.477–4.290) 0.001
with higher TG and lower HDL cholesterol; in addition,
population studies have elucidated genetic association of
APOC3withHDLcholesterollevels[28].Theseobservations
suggest that the functional APOC3 SNP mediates the widely
replicated associations of hypertriglyceridemia and lower
HDL cholesterol.
In summary, we demonstrated that common variants
of APOA1, APOC3, and APOA5 genes are associated with
ACS and contribute to the variation in human plasma TG
levels. Therefore, APOA5 variant was a signiﬁcant predictor
for high triglyceride/HDL risk and the APOA1/C3/A4/A5
haplotypes aﬀected dyslipidemia appreciably among ethnic
Chinese. Variations of these genes may be associated with
the development of ACSs. They could be served as a useful
genetic marker for diagnosis of ACSs.
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